The susceptibility of developing most major psychiatric disorders is determined in part by contributions from risk alleles at multiple genetic loci. The central aim of this article is to highlight evidence from studies of neurodegenerative disorders suggesting that some of these alleles are shared by more than one psychiatric disorder, and to explore mechanisms that may underly these pleiotropic effects. The identification of constellations of susceptibility alleles associated with particular mental disorders will provide opportunities for new insights into the molecular and cellular pathophysiology of these disorders, and will have a major impact on psychiatric research and clinical care. This approach to reducing the variance in etiopathogenesis is also likely to be important for achieving the optimal use of available treatments (maximizing effectiveness and minimizing side effects), and for the discovery of novel medications or other interventions. Molecular Psychiatry (2000) 5, 131-136.
During the past century, considerable effort has been devoted to the goal of formulating a nososology for mental disorders that has validity and clinical utility.
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),
1 was developed under the auspices of the American Psychiatric Association and is now widely used throughout the United States. In the DSM-IV and its antecedents, 'each of the mental disorders is conceptualized as a clinically significant behavioral or psychological syndrome or pattern that occurs in an individual and that is associated with present distress or disability or with a significantly increased risk of suffering, death, pain, disability, or an important loss of freedom.' These determinations have generally been rooted in empirical research studies employing epidemiological, clinical, and family methodologies. The resulting diagnoses of mental disorders have provided greater precision and uniformity in the descriptions of patients and research subjects. They have also contributed to a stronger foundation for guiding treatment, for making prognostic assessments regarding course and outcome, and for improving research studies that employ clinical populations.
However, it remains likely that few, if any, of the resulting diagnoses represent etiologically homo-geneous conditions, even among those whose phenotypes are the most extreme. The clinical features of patients with the same psychiatric diagnosis often vary considerably, and shared clinical characteristics among patients with different psychiatric diagnoses are common. Phenotypic overlap can be sufficiently large in some cases to fulfil diagnostic criteria for more than one mental disorder, and such 'comorbidity' occurs frequently for some disorders (eg mood disorders, anxiety disorders, and alcohol/substance use disorders). These observations may reflect, in part, the limitations inherent in previous phenomenologic approaches to defining mental disorders that are phenotypically and etiologically complex. The delineation of sources of phenotypic heterogeneity within and between psychiatric diagnoses is likely to yield important new insights into the etiology, clinical biology, therapeutics, and potential prevention of these disorders.
The susceptibility of developing most major psychiatric disorders is determined in part from contributions from risk alleles at multiple loci. The central aim of this article is to highlight evidence from studies of neurodegenerative disorders that some of these alleles appear to be shared among more than one psychiatric disorder. This is a significant observation and may contribute to a revised view of the clinical biology of these disorders. Differences among patients with the same diagnosis including clinical features (eg symptoms, treatment response, family history), course (eg remitting vs chronic), and natural history (eg which patients with depressive or psychotic disorders develop dementia later in life) may be determined in part from which shared alleles are inherited. Said differently, some of the phenotypic heterogeneity among patients with the same psychiatric diagnosis, and some of the characteristics shared by patients who have different psychiatric diagnoses, may be attributable to heterogeneity in the inheritance of a subset of common alleles.
APOE genotype in Alzheimer's disease and major depression
Alzheimer's disease (AD) is the most common cause of dementia among the elderly. [2] [3] [4] The defining features of AD include progressive, global cognitive impairment that develop in individuals whose brains manifest densities of senile plaques that exceed those expected for age. 5, 6 However, patients with this disorder manifest remarkable inter-individual variability in other clinical characteristics, including age at symptomatic onset; rate and pattern of progression; emergence of disturbances of mood, thought, perception, and behavior; development of extrapyramidal symptoms; and presence of a family history of AD-like dementia. Postmortem and genetic studies have also revealed considerable inter-individual variation in comorbid neuropathologic findings, brain neurochemical abnormalities, and contributions from particular genetic factors. This level of heterogeneity suggests that AD, as currently defined, may more closely resemble a syndrome with multiple contributing etiologies than a disease with a unitary cause. 7 Considerable progress has been made toward elucidating the genetics of AD during the past decade (for a review, see Zubenko) . 7 Age at symptomatic onset of dementia has become an important descriptive variable for classifying genes that influence the development of AD. Although they are uncommon, the majority of cases of AD that become symptomatic before the age of 60 appear to arise from highly penetrant, autosomal dominant genetic lesions. These include mutations in the structural genes for the amyloid precursor protein located on chromosome 21, 8,9 presenilin 1 located on chromosome 14, 10-13 presenilin 2 located on chromosome 1, 14, 15 as well as trisomy 21.
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More typical, later-onset forms of AD appear to be influenced by multiple susceptibility loci, combinations of which contribute to the development of this disorder. One such locus, APOE, is the structural gene for an apolipoprotein involved in lipid transport and metabolism. An association of the APOE ⑀4 allele with late-onset familial and sporadic AD has been observed in many populations throughout the world and is now well established. 17, 18 The ⑀4 allele appears to exert a dosage effect on the age at onset of typical cases of AD 19 as well as on the density of cortical senile plaques, [20] [21] [22] the histopathologic lesions that define this disorder. The APOE ⑀2 allele may confer an independent protective effect against the development of late onset AD. 23 Clinically significant depression is also a common mental disorder among the elderly that produces suffering, excess disability, and increased mortality among cognitively normal and cognitively impaired individuals alike. The relationship of major depression to irreversible dementia in late life is complex and remains an active area of clinical research in geriatric psychiatry. Longitudinal studies of cognitively intact elderly patients with major depression suggest that these patients do not progress to dementia at an agespecific rate that differs noticeably from that of the general population. [24] [25] [26] [27] In contrast, the preponderance of evidence indicates that elderly patients whose major depressions are complicated by cognitive impairment or subtle neurological signs or symptoms are at substantially increased risk for progression to irreversible dementia within a time frame of 2 or more years. [28] [29] [30] [31] [32] This latter group appears to include patients whose cognitive functioning improves concurrently with the treatment of their depressive syndromes ('pseudodementia' or 'reversible dementia of depression'). 32 Several studies have examined the APOE genotypes of elderly patients with major depression as a method of further exploring the clinical biology of this condition and its relationship to AD. The majority of the evidence has not revealed an association of the APOE ⑀4 allele with major depression in late life. [33] [34] [35] [36] In contrast, two published studies have reported a reduction in the frequency of the ⑀2 allele among elderly depressives comparable to that observed for patients with AD, suggesting that the ⑀2 allele exerts a protective effect on major depression as well as AD. 33, 36 In one of these studies, this association appeared stronger for elderly subjects whose first episode of major depression developed before age 45. 36 More recently, a reduction in the frequency of the APOE ⑀2 allele has been observed among patients with early-onset (Ͻ25 years), recurrent major depression compared to age and sexmatched controls who had no personal or family history of mood disorders. 37 While this apparent genetic link between AD and major depression in early to middle adulthood was not anticipated, it is consistent with several observations from clinical and epidemiologic studies. Seven casecontrol studies have identified clinical depression as a potential risk factor for AD, with associated odds ratios ranging from 1.7 to 5.0. [38] [39] [40] [41] [42] [43] [44] This relationship has been reported to persist or even increase when the analysis was restricted to depressive episodes that developed over 10 years before the onset of cognitive impairment. [41] [42] [43] [44] This result tends to exclude prodromal depression as the basis for the association of premorbid clinical depression with AD. Moreover, both a personal 45 and family history 46, 47 of major depression appear to be more common in AD patients who develop this behavioral syndrome than among those who do not. These last observations suggest an overlap in the pathophysiology of idiopathic major depression in younger patients and major depression in AD.
Clinical and neurobiological correlates of APOE and five novel candidate susceptibility loci for AD
The known AD susceptibility genes have been estimated to account for only a portion of the heritability of AD, 48 underscoring the importance of continuing the search for additional AD risk loci. With this goal in mind, we conducted a systematic survey of the human genome at an average resolution of 10 cM to identify simple sequence tandem repeat polymorphisms (SSTRPs) that target new risk genes for AD by virtue of linkage disequilibrium. 49, 50 Allelic associations with AD were observed for six of the 391 SSTRPs in the CHLC Human Screening Set/Weber Version 6: D1S518, D1S547, D10S1423, D12S1045, D19S178 and DXS1047. These allelic associations were replicated in an independent sample of autopsied AD cases and controls recruited from a geographically disparate site. The association of the large D19S178 alleles with AD appeared to arise from linkage disequilibrium with the APOE ⑀4 allele. None of the remaining SSTRPs were in close proximity to loci previously reported to influence the risk of developing AD. Instead, they appear to identify five novel AD susceptibility loci.
The clinical, neuropathologic, and neurochemical phenotypes of subjects who carry each of these candidate susceptibility alleles have been explored in a group of 50 autopsy-confirmed cases of AD who were followed longitudinally prior to death and lacked other brain diseases (Table 1) . [51] [52] [53] Consistent with previous reports, APOE ⑀4 carriers exhibited greater densities of senile plaques and neurofibrillary tangles than non-carriers. Carriers of the D12S1045 91-bp allele manifested an earlier age at symptomatic onset and death, increased density of neurofibrillary tangles, and a substantially greater reduction in cortical dopamine levels compared to AD patients who lacked this allele. This exaggerated reduction in cortical dopamine levels was also shared by subjects who carried risk alleles at the D10S1423 and DXS1047 loci. The latter two genotypic groups had similar phenotypes that also included the relative preservation of cortical norepinephrine levels. None of the alleles manifested an association with cortical choline acetyltransferase activities or serotonin levels.
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Carriers of the susceptibility alleles at the D1S518 and D1S547 loci did not differ phenotypically from the corresponding non-carrier genotype, although carriers of the D1S518 195-bp allele tended to have lower densities of cortical neurofibrillary tangles than non-carriers. The observations that several of these alleles modulate biological variables that are relevant to the pathophysiology of AD further supports their candidacy as AD susceptibility loci. Three of these six candidate risk alleles for AD appear to modulate cortical levels of the amine neurotransmitters dopamine and norepinephrine in important ways. As a result, their inheritance may influence the development of behavioral disturbances that are common sources of excess morbidity in AD. For example, the emergence of clinically significant depression in the context of primary dementia has been reported to be associated with degeneration of the dopaminergic neurons in the substantia nigra and noradrenergic neurons in the locus ceruleus. 47, 54, 55 These genotypes may also contribute to the development of psychosis, apathy, and extrapyramidal symptoms, and to inter-individual differences in response to the therapeutic or adverse effects of medications that involve these aminergic systems.
In addition to their relevance to the behavioral manifestations of AD, emerging evidence suggests that these AD susceptibility loci may be shared with psychiatric disorders whose symptomatic onsets occur earlier in life. Three independent groups have reported evidence for linkage of schizophrenia to D10S1423. [56] [57] [58] Evidence for linkage of bipolar disorder 59 and female alcoholism 60, 61 to a susceptibility locus at or near D10S1423 has also been reported. The pathophysiology of all three of these idiopathic disorders appears to include derangements of the aminergic nervous system. It is tempting to speculate that the effect of the D10S1423 genotype (or that of a nearby locus) on the central aminergic phenotypes of patients with AD may also contribute to abnormalities of those neuronal systems in mental disorders that become manifest in early or middle adulthood.
Possible mechanisms underlying pleiotropic effects of susceptibility alleles in AD and other mental disorders
Genes influence fundamental physiological processes at the molecular (eg transcription, translation, turnover), cellular (eg cell division, motility, molecular trafficking), and tissue/organ system (eg nutrition, detoxification, oxygenation) levels. Many alleles contribute modestly to the variance in these processes, while a smaller number have larger effects. The consequences of alterations in these processes depend on the physiological requirements of particular cells, their state of activity, and environmental conditions. This conceptual framework provides an opportunity to incorporate both inherited and environmental factors in the pathogenesis of mental disorders across the lifespan along with age-dependent changes in physiology.
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Disturbances in neuronal physiology and the functioning of neuronal networks are likely to result in behavioral phenotypes in the short term. Persistent impairments, especially in the context of age-related reductions in physiologic capacity, are likely to result in neuronal loss with more severe, pervasive, and less treatment-responsive clinical manifestations including cognitive impairment and dementia.
The biological consequences of inherited susceptibility loci for mental disorders may begin during development by altering the number and distributions of CNS neurons and supporting cells as well as their interconnections. Such developmental events are dependent not only on an appropriate number of cell divisions and migrations in space and time, but also a process of programmed cell death (apoptosis). Genetic and environmental modulation of cell sensitivity to apoptotic stimuli may affect CNS development in early life, as well as neuronal survival during CNS neurodegenerative disorders in late life. Depending on the extent of these effects and the cell types affected, such individuals may be predisposed to the emergence of behavioral disorders throughout life as well as a premature neuronal loss in later life. The pattern of neuronal dysfunction and eventual loss may extend not only to the initial neuronal populations affected in development but also to those that rely on them for trophic or other supporting influences.
Genetically-influenced variation in extraneuronal support functions (eg nutrition, oxygenation, detoxification, repair mechanisms) may also contribute to the neuronal dysfunction and eventual cell death. Aging is typically associated with decrements in the capacity of those physiological support mechanisms. 62 As a result, interactions between the biological consequences of susceptibility alleles for early-onset mental disorders with age-associated alterations in physiology may further contribute to the emergence of neurodegeneration in later life. Finally, environmental consequences of mental disorders in early to midlife such as excessive stress and hypercortisolemia; greater burden of medical problems including the consequences of accidents and trauma; increased exposure to drugs (recreational and therapeutic), alcohol, and toxins; and inattention to healthcare may also contribute to CNS dysfunction and neurodegeneration.
How do susceptibility alleles for mental disorders affect particular neuronal populations at different times during the life cycle? Differences in gene expression contribute in important ways to the differentiation of ancestral cells into mature neuronal cell types. This process may include the activation or inactivation of at least some of the susceptibility loci for mental disorders. Alternatively, neuronal specificity may be conferred by cell-specific distributions of protein or other cellular constituents that are required for the gene products of susceptibility alleles to exert their pathologic effects. The latter mechanism appears to account for the selective degeneration of the caudate and lentiform nuclei in Huntington's disease, since the expression of the abnormally expanded HD gene appears to be indistinguishable from that of the normal gene, and is not correlated with the affected brain regions. 63, 64 Susceptibility alleles that modulate extraneuronal support mechanisms would be expected to selectively affect neurons that are most dependent on the support mechanism(s) affected. For example, brain cells have a very low capacity to synthesize choline despite the importance of this compound in neuronal metabolism. 65 As a result, they depend almost entirely on the availability of dietary choline for their existence. The especially high demand for choline by cholinergic neurons places these cells at disproportionate risk as the result of genetic or age-related decreases in the uptake of circulating choline into the brain. Increased activity of the cholinergic nervous system in subjects with depression 55 along with age-specific decline in choline uptake into the brain 66 may contribute to the emergence of memory impairment and dementia.
Significance and conclusion
Uncertainty in the phenotypes influenced by susceptibility loci for mental disorders increases the difficulty of detecting such loci by current experimental strategies whose required sample sizes typically approach the limits of feasibility. A common method of addressing this issue is to designate only those individuals in a sample who manifest an extreme core phenotype as 'affected', while the remainder are classified as 'unknown'. Alternative complementary approaches employ evidence from epidemiologic, family, or treatment studies to define phenotypes of interest, or evaluate phenotypes defined by graduated severity criteria in an iterative way. All of these strategies suffer from inefficiencies due to the inability to unambiguously specify a phenotype for study. An additional limitation associated with genetic studies of late-onset disorders like AD is that most family members have not lived through the age of risk, and that many of the remainder who have lived long enough to be diagnostically informative are deceased.
It is not suprising then that most initial genetic investigations of mental disorders have generated candidate susceptibility loci that require evaluation by multiple analytic methods and replication in independent samples for validation. Subsequent evaluations of well-characterized clinical samples will shed considerable light on the phenotypic expression of these genes. Continued exploration of the specificity of such loci are also likely to define unanticipated pleiotropic effects and phenotypic overlaps.
The identification of constellations of susceptibility alleles associated with particular mental disorders will provide new insights into the molecular and cellular pathophysiology of these disorders, and will contribute to a pathophysiology-based classification system that will have a major impact on psychiatric research and clinical care. This approach to reducing the variance in etiopathogenesis is likely to be important for the optimal use of available treatments, and the discovery of novel medications or other interventions that have beneficial effects on preventing, forestalling the onset, or ameliorating the symptoms of some genetic subtypes of psychiatric disorders but not others.
Most mental disorders defined in the DSM-IV reflect syndromes, like anemia, that may encompass numerous pathogenetic pathways across affected individuals which lead to the production of a common phenotype. However, only a limited subset of these pathways are operative within a single individual. As a result, only the subset of anemic individuals who suffer from pernicious anemia experience the restoration of their red cell mass and avoid neurological damage in response to vitamin B 12 injections. It is doubtful that the benefit of this efficacious treatment would have been detected by studies that focused on the syndromic presentation of anemia without further attention to biologically meaningful subtypes. The relevance of this example to the pharmacotherapeutics of psychiatric disorders will continue to grow as medications with increasingly selective pharmacologic properties become available.
